Cystatin C: An emerging biomarker in cardiovascular disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 164-179

  Angelidis, Christos ^a   Deftereos, Spyridon ^a   Giannopoulos, Georgios ^a,c   Anatoliotakis, Nikolaos ^a   Bouras, Georgios ^a   Hatzis, Georgios ^b   Panagopoulou, Vasiliki ^a   Pyrgakis, Vlasios ^a   Cleman, Michael W ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Cardiovascular disease; Chronic kidney disease; Coronary artery disease; Cystatin C; Cysteinyl cathepsins; Heart failure; Peripheral arterial disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CATHEPSIN B; COLLAGEN; CREATININE; CYSTATIN B; CYSTATIN C; CYSTATIN M; CYSTATIN S; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; KININOGEN; LEGUMAIN; MATRIX METALLOPROTEINASE; PLASMA PROTEIN; SERINE PROTEINASE; STEFIN A; THYROID HORMONE; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HUMAN; IMMUNODIFFUSION; INFLAMMATION; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOMETRY; PHYSICAL CHEMISTRY; SYSTEMATIC REVIEW; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CATHEPSINS; CYSTATIN C; HEART FAILURE; HUMANS; KIDNEY; MOLECULAR SEQUENCE DATA; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; STROKE;

EID: 84877795266     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313020006     Document Type: Article

References (209)

1. Clausen, J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med, 1961, 107, 170-172.
2. Macpherson, C. F.; Cosgrove, J. B. Immunochemical evidence for a gamma globulin peculiar to cerebrospinal fluid. Can J Biochem Physiol, 1961, 39, 1567-1574.
3. Butler, E. A.; Flynn, F. V. The occurrence of post-gamma protein in urine: a new protein abnormality. J Clin Pathol, 1961, 14, 172-178.
4. Cejka, J.; Fleischmann, L. E. Post-globulin: isolation and physicochemical characterization. Arch Biochem Biophys, 1973, 157, 168-176.
5. Hochwald, G. M.; Pepe, A. J.; Thorbecke, G. J. Trace proteins in biological fluids. IV. Physicochemical properties and sites of formation of gamma-trace and beta-trace proteins. Proc Soc Exp Biol Med, 1967, 124, 961-966.
6. Hochwald, G. M.; Thorbecke, G. J. Use of an antiserum against cerebrospinal fluid in demonstration of trace proteins in biological fluids. Proc Soc Exp Biol Med, 1962, 109, 91-95.
7. Kjellin, K. G.; Stibler, H. Protein patterns of cerebrospinal fluid in hereditary ataxias and hereditary spastic paraplegia. J Neurol Sci, 1975, 25, 65-74.
8. Laterre, E. C.; Heremans, J. F.; Carbonara, A. Immunological Comparison Of Some Proteins Found In Cerebrospinal Fluid, Urine And Extracts From Brain And Kidney. Clin Chim Acta, 1964, 10, 197-209.
9. Souverijn, J. H.; Peet, R.; Smit, W. G.; Serree, H. M.; Bruyn, G. W. The HAF enigma: origin and clinical consequences of the appearance of high alkaline fractions on isoelectric focusing patterns of cerebrospinal fluid. J Neurol Sci, 1990, 97, 117-128.
10. Grubb, A.; Lofberg, H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci U S A, 1982, 79, 3024-3027.
11. Abrahamson, M.; Grubb, A.; Olafsson, I.; Lundwall, A. Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C. FEBS Lett, 1987, 216, 229-233.
12. Abrahamson, M.; Islam, M. Q.; Szpirer, J.; Szpirer, C.; Levan, G. The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20. Hum Genet, 1989, 82, 223-226.
13. Abrahamson, M.; Olafsson, I.; Palsdottir, A.; Ulvsback, M.; Lundwall, A.; Jensson, O.; Grubb, A. Structure and expression of the human cystatin C gene. Biochem J, 1990, 268, 287-294.
14. Brzin, J.; Popovic, T.; Turk, V.; Borchart, U.; Machleidt, W. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun, 1984, 118, 103-109.
15. Barrett, A. J.; Davies, M. E.; Grubb, A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun, 1984, 120, 631-636.
16. Schwabe, C.; Anastasi, A.; Crow, H.; McDonald, J. K.; Barrett, A. J. Cystatin. Amino acid sequence and possible secondary structure. Biochem J, 1984, 217, 813-817.
17. Turk, V.; Bode, W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett, 1991, 285, 213-219.
18. Barrett, A. J. [57] Cystatin, the egg white inhibitor of cysteine proteinases. In Methods in Enzymology, Laszlo, L., Ed. Academic Press: 1981; Vol. Volume 80, pp 771-778.
19. Fossum, K.; Whitaker, J. R. Ficin and papain inhibitor from chicken egg white. Arch Biochem Biophys, 1968, 125, 367-375.
20. Barrett, A. J.; Fritz, H.; Grubb, A.; Isemura, S.; Jarvinen, M.; Katunuma, N.; Machleidt, W.; Muller-Esterl, W.; Sasaki, M.; Turk, V. Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J, 1986, 236, 312.
21. Abrahamson, M.; Ritonja, A.; Brown, M. A.; Grubb, A.; Machleidt, W.; Barrett, A. J. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem, 1987, 262, 9688-9694.
22. Bjork, I.; Brieditis, I.; Raub-Segall, E.; Pol, E.; Hakansson, K.; Abrahamson, M. The importance of the second hairpin loop of cystatin C for proteinase binding. Characterization of the interaction of Trp-106 variants of the inhibitor with cysteine proteinases. Biochemistry, 1996, 35, 10720-10726.
23. Hall, A.; Dalboge, H.; Grubb, A.; Abrahamson, M. Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition. Biochem J, 1993, 291 (Pt 1), 123-129.
24. Hall, A.; Ekiel, I.; Mason, R. W.; Kasprzykowski, F.; Grubb, A.; Abrahamson, M. Structural basis for different inhibitory specificities of human cystatins C and D. Biochemistry, 1998, 37, 4071-4079.
25. Hall, A.; Hakansson, K.; Mason, R. W.; Grubb, A.; Abrahamson, M. Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. J Biol Chem, 1995, 270, 5115-5121.
26. Lindahl, P.; Ripoll, D.; Abrahamson, M.; Mort, J. S.; Storer, A. C. Evidence for the interaction of valine-10 in cystatin C with the S2 subsite of cathepsin B. Biochemistry, 1994, 33, 4384-4392.
27. Mason, R. W.; Sol-Church, K.; Abrahamson, M. Amino acid substitutions in the N-terminal segment of cystatin C create selective protein inhibitors of lysosomal cysteine proteinases. Biochem J, 1998, 330 (Pt 2), 833-838.
28. Chen, J. M.; Dando, P. M.; Rawlings, N. D.; Brown, M. A.; Young, N. E.; Stevens, R. A.; Hewitt, E.; Watts, C.; Barrett, A. J. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem, 1997, 272, 8090-8098.
29. Alvarez-Fernandez, M.; Barrett, A. J.; Gerhartz, B.; Dando, P. M.; Ni, J.; Abrahamson, M. Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem, 1999, 274, 19195-19203.
30. Bode, W.; Engh, R.; Musil, D.; Thiele, U.; Huber, R.; Karshikov, A.; Brzin, J.; Kos, J.; Turk, V. The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J, 1988, 7, 2593-2599.
31. Kolodziejczyk, R.; Michalska, K.; Hernandez-Santoyo, A.; Wahlbom, M.; Grubb, A.; Jaskolski, M. Crystal structure of human cystatin C stabilized against amyloid formation. FEBS J, 2010, 277, 1726-1737.
32. Janowski, R.; Kozak, M.; Jankowska, E.; Grzonka, Z.; Grubb, A.; Abrahamson, M.; Jaskolski, M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol, 2001, 8, 316-320.
33. Janowski, R.; Abrahamson, M.; Grubb, A.; Jaskolski, M. Domain swapping in N-truncated human cystatin C. J Mol Biol, 2004, 341, 151-160.
34. Janowski, R.; Kozak, M.; Abrahamson, M.; Grubb, A.; Jaskolski, M. 3D domain-swapped human cystatin C with amyloidlike intermolecular beta-sheets. Proteins, 2005, 61, 570-578.
35. Grzonka, Z.; Jankowska, E.; Kasprzykowski, F.; Kasprzykowska, R.; Lankiewicz, L.; Wiczk, W.; Wieczerzak, E.; Ciarkowski, J.; Drabik, P.; Janowski, R.; Kozak, M.; Jaskolski, M.; Grubb, A. Structural studies of cysteine proteases and their inhibitors. Acta Biochim Pol, 2001, 48, 1-20.
36. Lindahl, P.; Abrahamson, M.; Bjork, I. Interaction of recombinant human cystatin C with the cysteine proteinases papain and actinidin. Biochem J, 1992, 281 (Pt 1), 49-55.
37. Grubb, A. O. Cystatin C--properties and use as diagnostic marker. Adv Clin Chem, 2000, 35, 63-99.
38. Schnittger, S.; Rao, V. V.; Abrahamson, M.; Hansmann, I. Cystatin C (CST3), the candidate gene for hereditary cystatin C amyloid angiopathy (HCCAA), and other members of the cystatin gene family are clustered on chromosome 20p11.2. Genomics, 1993, 16, 50-55.
39. Lignelid, H.; Jacobsson, B. Cystatin C in the human pancreas and gut: an immunohistochemical study of normal and neoplastic tissues. Virchows Arch A Pathol Anat Histopathol, 1992, 421, 491-495.
40. Lignelid, H.; Collins, V. P.; Jacobsson, B. Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol, 1997, 93, 494-500.
41. Jacobsson, B.; Lignelid, H.; Bergerheim, U. S. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology, 1995, 26, 559-564.
42. Chapman, H. A., Jr.; Reilly, J. J., Jr.; Yee, R.; Grubb, A. Identification of cystatin C, a cysteine proteinase inhibitor, as a major secretory product of human alveolar macrophages in vitro. Am Rev Respir Dis, 1990, 141, 698-705.
43. Bjarnadottir, M.; Grubb, A.; Olafsson, I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest, 1995, 55, 617-623.
44. Ni, J.; Fernandez, M. A.; Danielsson, L.; Chillakuru, R. A.; Zhang, J.; Grubb, A.; Su, J.; Gentz, R.; Abrahamson, M. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J Biol Chem, 1998, 273, 24797-24804.
45. Simonsen, O.; Grubb, A.; Thysell, H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest, 1985, 45, 97-101.
46. Grubb, A.; Simonsen, O.; Sturfelt, G.; Truedsson, L.; Thysell, H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand, 1985, 218, 499-503.
47. Kyhse-Andersen, J.; Schmidt, C.; Nordin, G.; Andersson, B.; Nilsson-Ehle, P.; Lindstrom, V.; Grubb, A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem, 1994, 40, 1921-1926.
48. Newman, D. J.; Thakkar, H.; Edwards, R. G.; Wilkie, M.; White, T.; Grubb, A. O.; Price, C. P. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int, 1995, 47, 312-318.
49. Galteau, M. M.; Guyon, M.; Gueguen, R.; Siest, G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med, 2001, 39, 850-857.
50. Knight, E. L.; Verhave, J. C.; Spiegelman, D.; Hillege, H. L.; de Zeeuw, D.; Curhan, G. C.; de Jong, P. E. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int, 2004, 65, 1416-1421.
51. Ichihara, K.; Saito, K.; Itoh, Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med, 2007, 45, 1232-1236.
52. Muntner, P.; Winston, J.; Uribarri, J.; Mann, D.; Fox, C. S. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med, 2008, 121, 341-348.
53. Evangelopoulos, A. A.; Vallianou, N. G.; Bountziouka, V. P.; Giotopoulou, A. N.; Bonou, M. S.; Barbetseas, J.; Avgerinos, P. C.; Panagiotakos, D. B. The impact of demographic characteristics and lifestyle in the distribution of cystatin C values in a healthy greek adult population. Cardiol Res Pract, 2010, 2011, 163-281.
54. Bokenkamp, A.; Domanetzki, M.; Zinck, R.; Schumann, G.; Byrd, D.; Brodehl, J. Cystatin C--a new marker of glomerular filtration rate in children independent of age and height. Pediatrics, 1998, 101, 875-881.
55. Cataldi, L.; Mussap, M.; Bertelli, L.; Ruzzante, N.; Fanos, V.; Plebani, M. Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values. Am J Perinatol, 1999, 16, 287-295.
56. Randers, E.; Krue, S.; Erlandsen, E. J.; Danielsen, H.; Hansen, L. G. Reference interval for serum cystatin C in children. Clin Chem, 1999, 45, 1856-1858.
57. Finney, H.; Newman, D. J.; Thakkar, H.; Fell, J. M.; Price, C. P. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child, 2000, 82, 71-75.
58. Bahar, A.; Yilmaz, Y.; Unver, S.; Gocmen, I.; Karademir, F. Reference values of umbilical cord and third-day cystatin C levels for determining glomerular filtration rates in newborns. J Int Med Res, 2003, 31, 231-235.
59. Norlund, L.; Fex, G.; Lanke, J.; Von Schenck, H.; Nilsson, J. E.; Leksell, H.; Grubb, A. Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2-microglobulin/cystatin C-ratio. Scand J Clin Lab Invest, 1997, 57, 463-470.
60. Erlandsen, E. J.; Randers, E.; Kristensen, J. H. Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med, 1998, 36, 393-397.
61. Finney, H.; Newman, D. J.; Price, C. P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem, 2000, 37 (Pt 1), 49-59.
62. Vinge, E.; Lindergard, B.; Nilsson-Ehle, P.; Grubb, A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest, 1999, 59, 587-592.
63. Macdonald, J.; Marcora, S.; Jibani, M.; Roberts, G.; Kumwenda, M.; Glover, R.; Barron, J.; Lemmey, A. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis, 2006, 48, 712-719.
64. den Hollander, J. G.; Wulkan, R. W.; Mantel, M. J.; Berghout, A. Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction? Clin Chem, 2003, 49, 1558-1559.
65. Fricker, M.; Wiesli, P.; Brandle, M.; Schwegler, B.; Schmid, C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int, 2003, 63, 1944-1947.
66. Jayagopal, V.; Keevil, B. G.; Atkin, S. L.; Jennings, P. E.; Kilpatrick, E. S. Paradoxical changes in cystatin C and serum creatinine in patients with hypo-and hyperthyroidism. Clin Chem, 2003, 49, 680-681.
67. Manetti, L.; Pardini, E.; Genovesi, M.; Campomori, A.; Grasso, L.; Morselli, L. L.; Lupi, I.; Pellegrini, G.; Bartalena, L.; Bogazzi, F.; Martino, E. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest, 2005, 28, 346-349.
68. Wiesli, P.; Schwegler, B.; Spinas, G. A.; Schmid, C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta, 2003, 338, 87-90.
69. Schmid, C.; Ghirlanda-Keller, C.; Zwimpfer, C.; Zoidis, E. Triiodothyronine stimulates cystatin C production in bone cells. Biochem Biophys Res Commun, 2012, 419, 425-430.
70. Kotajima, N.; Yanagawa, Y.; Aoki, T.; Tsunekawa, K.; Morimura, T.; Ogiwara, T.; Nara, M.; Murakami, M. Influence of thyroid hormones and transforming growth factor-beta1 on cystatin C concentrations. J Int Med Res, 2010, 38, 1365-1373.
71. Goede, D. L.; Wiesli, P.; Brandle, M.; Bestmann, L.; Bernays, R. L.; Zwimpfer, C.; Schmid, C. Effects of thyroxine replacement on serum creatinine and cystatin C in patients with primary and central hypothyroidism. Swiss Med Wkly, 2009, 139, 339-344.
72. Ozden, T. A.; Tekerek, H.; Bas, F.; Darendeliler, F. Effect of hypo-and euthyroid status on serum cystatin C levels. J Clin Res Pediatr Endocrinol, 2010, 2, 155-158.
73. Kimmel, M.; Braun, N.; Alscher, M. D. Influence of thyroid function on different kidney function tests. Kidney Blood Press Res, 2012, 35, 9-17.
74. Cimerman, N.; Brguljan, P. M.; Krasovec, M.; Suskovic, S.; Kos, J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta, 2000, 300, 83-95.
75. Risch, L.; Herklotz, R.; Blumberg, A.; Huber, A. R. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem, 2001, 47, 2055-2059.
76. Poge, U.; Gerhardt, T.; Bokenkamp, A.; Stoffel-Wagner, B.; Klehr, H. U.; Sauerbruch, T.; Woitas, R. P. Time course of low molecular weight proteins in the early kidney transplantation period-- influence of corticosteroids. Nephrol Dial Transplant, 2004, 19, 2858-2863.
77. Abbink, F. C.; Laarman, C. A.; Braam, K. I.; van Wijk, J. A.; Kors, W. A.; Bouman, A. A.; Spreeuwenberg, M. D.; Stoffel-Wagner, B.; Bokenkamp, A. Beta-trace protein is not superior to cystatin C for the estimation of GFR in patients receiving corticosteroids. Clin Biochem, 2008, 41, 299-305.
78. Bokenkamp, A.; van Wijk, J. A.; Lentze, M. J.; Stoffel-Wagner, B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem, 2002, 48, 1123-1126.
79. Randers, E.; Kornerup, K.; Erlandsen, E. J.; Hasling, C.; Danielsen, H. Cystatin C levels in sera of patients with acute infectious diseases with high C-reactive protein levels. Scand J Clin Lab Invest, 2001, 61, 333-335.
80. Kitamura, H.; Kamon, H.; Sawa, S.; Park, S. J.; Katunuma, N.; Ishihara, K.; Murakami, M.; Hirano, T. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity, 2005, 23, 491-502.
81. Frendeus, K. H.; Wallin, H.; Janciauskiene, S.; Abrahamson, M. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int J Biochem Cell Biol, 2009, 41, 2262-2269.
82. Xu, Y.; Schnorrer, P.; Proietto, A.; Kowalski, G.; Febbraio, M. A.; Acha-Orbea, H.; Dickins, R. A.; Villadangos, J. A. IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol, 2011, 186, 3666-3673.
83. Warfel, A. H.; Cardozo, C.; Yoo, O. H.; Zucker-Franklin, D. Cystatin C and cathepsin B production by alveolar macrophages from smokers and nonsmokers. J Leukoc Biol, 1991, 49, 41-47.
84. Rokadia, H. K.; Agarwal, S. Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES). Lung, 2012, 190, 283-290.
85. Naour, N.; Fellahi, S.; Renucci, J. F.; Poitou, C.; Rouault, C.; Basdevant, A.; Dutour, A.; Alessi, M. C.; Bastard, J. P.; Clement, K.; Guerre-Millo, M. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring), 2009, 17, 2121-2126.
86. Codoner-Franch, P.; Ballester-Asensio, E.; Martinez-Pons, L.; Vallecillo-Hernandez, J.; Navarro-Ruiz, A.; del Valle-Perez, R. Cystatin C, cardiometabolic risk, and body composition in severely obese children. Pediatr Nephrol, 2011, 26, 301-307.
87. Guerre-Millo, M. Serum cystatin C concentrations are increased in human obesity in relation to over-production by the adipose tissue. Obesity (Silver Spring), 2012, 20, 1755.
88. Lafarge, J. C.; Naour, N.; Clement, K.; Guerre-Millo, M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie, 2010, 92, 1580-1586.
89. Tenstad, O.; Roald, A. B.; Grubb, A.; Aukland, K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest, 1996, 56, 409-414.
90. Sjöström, P.; Tidman, M.; Jones, I. Determination of the production rate and non renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scandinavian Journal of Clinical & Laboratory Investigation, 2005, 65, 111-124.
91. Kaseda, R.; Iino, N.; Hosojima, M.; Takeda, T.; Hosaka, K.; Kobayashi, A.; Yamamoto, K.; Suzuki, A.; Kasai, A.; Suzuki, Y.; Gejyo, F.; Saito, A. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun, 2007, 357, 1130-1134.
92. Odera, K.; Goto, S.; Takahashi, R. Age-related change of endocytic receptors megalin and cubilin in the kidney in rats. Biogerontology, 2007, 8, 505-515.
93. Zhai, X. Y.; Nielsen, R.; Birn, H.; Drumm, K.; Mildenberger, S.; Freudinger, R.; Moestrup, S. K.; Verroust, P. J.; Christensen, E. I.; Gekle, M. Cubilin-and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int, 2000, 58, 1523-1533.
94. van Rossum, L. K.; Zietse, R.; Vulto, A. G.; de Rijke, Y. B. Renal extraction of cystatin C vs 125I-iothalamate in hypertensive patients. Nephrol Dial Transplant, 2006, 21, 1253-1256.
95. Delanaye, P.; Cavalier, E.; Chapelle, J. P.; Krzesinski, J. M.; Froissart, M. Renal extraction of cystatin C. Nephrol Dial Transplant, 2006, 21, 3333.
96. Ix, J. H. Utility of cystatin C measurement--precision or secretion? Nephrol Dial Transplant, 2006, 21, 3614.
97. Poge, U.; Gerhardt, T.; Woitas, R. P. Renal handling of cystatin C. Nephrol Dial Transplant, 2007, 22, 1267-1268.
98. Lofberg, H.; Grubb, A. O. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand J Clin Lab Invest, 1979, 39, 619-626.
99. Kyhse-Andersen, J.; Schmidt, C.; Nordin, G.; Andersson, B.; Nilsson-Ehle, P.; Lindström, V.; Grubb, A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem, 1994, 40, 1921-1926.
100. Pergande, M.; Jung, K. Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies. Clin Chem, 1993, 39, 1885-1890.
101. Finney, H.; Newman, D. J.; Gruber, W.; Merle, P.; Price, C. P. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem, 1997, 43, 1016-1022.
102. Mussap, M.; Ruzzante, N.; Varagnolo, M.; Plebani, M. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurement of human cystatin C. Clin Chem Lab Med, 1998, 36, 859-865.
103. Erlandsen, E. J.; Randers, E.; Kristensen, J. H. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest, 1999, 59, 1-8.
104. Flodin, M.; Hansson, L. O.; Larsson, A. Evaluation of Dade Behring N Latex Cystatin C reagent on Abbott ci8200. Ups J Med Sci, 2006, 111, 209-213.
105. Sunde, K.; Nilsen, T.; Flodin, M. Performance characteristics of a cystatin C immunoassay with avian antibodies. Ups J Med Sci, 2007, 112, 21-37.
106. Myers, G. L.; Miller, W. G.; Coresh, J.; Fleming, J.; Greenberg, N.; Greene, T.; Hostetter, T.; Levey, A. S.; Panteghini, M.; Welch, M.; Eckfeldt, J. H. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem, 2006, 52, 5-18.
107. Delanaye, P.; Pieroni, L.; Abshoff, C.; Lutteri, L.; Chapelle, J. P.; Krzesinski, J. M.; Hainque, B.; Cavalier, E. Analytical study of three cystatin C assays and their impact on cystatin C-based GFR-prediction equations. Clin Chim Acta, 2008, 398, 118-124.
108. Hossain, M. A.; Emara, M.; El Moselhi, H.; Shoker, A. Comparing measures of cystatin C in human sera by three methods. Am J Nephrol, 2009, 29, 381-391.
109. Flodin, M.; Hansson, L. O.; Larsson, A. Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls. Clin Chem Lab Med, 2006, 44, 1481-1485.
110. Thuillier, F.; Demarquilly, C.; Szymanowicz, A.; Gaillard, C.; Boniface, M.; Braidy, C.; Daunizeau, A.; Gascht, D.; Gruson, A.; Lagabrielle, J. F.; Lasnier, E.; Lemdani, M.; Macchi, V.; Poulin, G.; de Sainte Hermine, C.; Sancho, J.; Schellenberg, F.; Sevin, O.; Vaubourdolle, M. [Nephelometry or turbidimetry for the determination of albumin, ApoA, CRP, haptoglobin, IgM and transthyretin: which choice?]. Ann Biol Clin (Paris), 2008, 66, 63-78.
111. Madero, M.; Sarnak, M. J.; Stevens, L. A. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens, 2006, 15, 610-616.
112. Delanaye, P.; Cavalier, E.; Krzesinski, J. M.; Mariat, C. Cystatin C-based equations: don't repeat the same errors with analytical considerations. Nephrol Dial Transplant, 2008, 23, 1065; author reply 1065-1066.
113. Grubb, A.; Nordin, G. Notable steps in obtaining improved estimates for glomerular filtration rate. Clin Chem, 2006, 52, 169-170.
114. Blirup-Jensen, S.; Grubb, A.; Lindstrom, V.; Schmidt, C.; Althaus, H. Standardization of Cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest Suppl, 2008, 241, 67-70.
115. Tian, S.; Kusano, E.; Ohara, T.; Tabei, K.; Itoh, Y.; Kawai, T.; Asano, Y. Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol, 1997, 48, 104-108.
116. Xu, X.; Zou, J.; Ding, X.; Xin, D.; Ren, Y. Clinical value of serum cystatin C by ELISA for estimation of glomerular filtration rate. Journal of Clinical Laboratory Analysis, 2004, 18, 61-64.
117. Zahran, A.; Qureshi, M.; Shoker, A. Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol Dial Transplant, 2007, 22, 2659-2668.
118. Ristiniemi, N.; Qin, Q. P.; Postnikov, A.; Grubb, A.; Pettersson, K. Dry-reagent double-monoclonal assay for cystatin C. Clin Chem, 2010, 56, 1424-1431.
119. Pettersson, K.; von Lode, P.; Eriksson, S.; Lövgren, J.; Takalo, H. Multi-Assay Point-of-Care Platform: Highly Sensitive Time-Resolved Fluorometric Detection in Combination with a Universal All-In-One Assay Format. Point of Care, 2003, 2, 225-232.
120. Ristiniemi, N.; Savage, C.; Bruun, L.; Pettersson, K.; Lilja, H.; Christensson, A. Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function. Nephrol Dial Transplant, 2012, 27, 682-687.
121. Ristiniemi, N.; Qin, Q. P.; Lindstrom, V.; Grubb, A.; Pettersson, K. Quantification of cystatin C by time-resolved fluorometry-based immunoassays. J Immunol Methods, 2012, 378, 56-61.
122. Foley, R. N.; Parfrey, P. S.; Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 1998, 32, S112-119.
123. Go, A. S.; Chertow, G. M.; Fan, D.; McCulloch, C. E.; Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004, 351, 1296-1305.
124. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis, 2005, 45, S1-153.
125. Berl, T.; Henrich, W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol, 2006, 1, 8-18.
126. Ninomiya, T.; Kiyohara, Y.; Kubo, M.; Tanizaki, Y.; Doi, Y.; Okubo, K.; Wakugawa, Y.; Hata, J.; Oishi, Y.; Shikata, K.; Yonemoto, K.; Hirakata, H.; Iida, M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int, 2005, 68, 228-236.
127. Matsushita, K.; van der Velde, M.; Astor, B. C.; Woodward, M.; Levey, A. S.; de Jong, P. E.; Coresh, J.; Gansevoort, R. T. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010, 375, 2073-2081.
128. Tonelli, M.; Muntner, P.; Lloyd, A.; Manns, B. J.; James, M. T.; Klarenbach, S.; Quinn, R. R.; Wiebe, N.; Hemmelgarn, B. R. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med, 2011, 154, 12-21.
129. Schiffrin, E. L.; Lipman, M. L.; Mann, J. F. Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007, 116, 85-97.
130. Sarnak, M. J.; Levey, A. S.; Schoolwerth, A. C.; Coresh, J.; Culleton, B.; Hamm, L. L.; McCullough, P. A.; Kasiske, B. L.; Kelepouris, E.; Klag, M. J.; Parfrey, P.; Pfeffer, M.; Raij, L.; Spinosa, D. J.; Wilson, P. W. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation, 2003, 108, 2154-2169.
131. Tonelli, M.; Muntner, P.; Lloyd, A.; Manns, B. J.; Klarenbach, S.; Pannu, N.; James, M. T.; Hemmelgarn, B. R. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet, 2012, 380, 807-814.
132. Polonsky, T. S.; Bakris, G. L. Chronic kidney disease: a coronary heart disease equivalent? Lancet, 2012, 380, 783-785.
133. Taglieri, N.; Koenig, W.; Kaski, J. C. Cystatin C and cardiovascular risk. Clin Chem, 2009, 55, 1932-1943.
134. Madero, M.; Sarnak, M. J. Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens, 2009, 18, 258-263.
135. Emberson, J. R.; Haynes, R.; Dasgupta, T.; Mafham, M.; Landray, M. J.; Baigent, C.; Clarke, R. Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J Intern Med, 2010, 268, 145-154.
136. Deo, R.; Sotoodehnia, N.; Katz, R.; Sarnak, M. J.; Fried, L. F.; Chonchol, M.; Kestenbaum, B.; Psaty, B. M.; Siscovick, D. S.; Shlipak, M. G. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes, 2010, 3, 159-164.
137. Cepeda, J.; Tranche-Iparraguirre, S.; Marin-Iranzo, R.; Fernandez-Rodriguez, E.; Riesgo-Garcia, A.; Garcia-Casas, J.; Hevia-Rodriguez, E. [Cystatin C and cardiovascular risk in the general population]. Rev Esp Cardiol, 2010, 63, 415-422.
138. Vigil, L.; Lopez, M.; Condes, E.; Varela, M.; Lorence, D.; Garcia-Carretero, R.; Ruiz, J. Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population. J Am Soc Hypertens, 2009, 3, 201-209.
139. Ito, H.; Pacold, I. V.; Durazo-Arvizu, R.; Liu, K.; Shilipak, M. G.; Goff, D. C., Jr.; Tracy, R. P.; Kramer, H. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis. Am J Epidemiol, 2011, 174, 949-957.
140. Turk, B.; Turk, V.; Turk, D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem, 1997, 378, 141-150.
141. Rawlings, N. D.; Morton, F. R.; Kok, C. Y.; Kong, J.; Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res, 2008, 36, D320-325.
142. Coulombe, R.; Grochulski, P.; Sivaraman, J.; Menard, R.; Mort, J. S.; Cygler, M. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J, 1996, 15, 5492-5503.
143. Dubin, G. Proteinaceous cysteine protease inhibitors. Cell Mol Life Sci, 2005, 62, 653-669.
144. Cheng, X. W.; Shi, G. P.; Kuzuya, M.; Sasaki, T.; Okumura, K.; Murohara, T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation, 2012, 125, 1551-1562.
145. Obermajer, N.; Jevnikar, Z.; Doljak, B.; Kos, J. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res, 2008, 49, 193-196.
146. Punturieri, A.; Filippov, S.; Allen, E.; Caras, I.; Murray, R.; Reddy, V.; Weiss, S. J. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med, 2000, 192, 789-799.
147. Cheng, X. W.; Murohara, T.; Kuzuya, M.; Izawa, H.; Sasaki, T.; Obata, K.; Nagata, K.; Nishizawa, T.; Kobayashi, M.; Yamada, T.; Kim, W.; Sato, K.; Shi, G. P.; Okumura, K.; Yokota, M. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol, 2008, 173, 358-369.
148. Cheng, X. W.; Obata, K.; Kuzuya, M.; Izawa, H.; Nakamura, K.; Asai, E.; Nagasaka, T.; Saka, M.; Kimata, T.; Noda, A.; Nagata, K.; Jin, H.; Shi, G. P.; Iguchi, A.; Murohara, T.; Yokota, M. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension, 2006, 48, 979-987.
149. Barka, T.; van der Noen, H. Expression of the cysteine proteinase inhibitor cystatin C gene in rat heart: use of digoxigenin-labeled probes generated by polymerase chain reaction directly for in situ and northern blot hybridizations. J Histochem Cytochem, 1993, 41, 1863-1867.
150. Shi, G. P.; Sukhova, G. K.; Grubb, A.; Ducharme, A.; Rhode, L. H.; Lee, R. T.; Ridker, P. M.; Libby, P.; Chapman, H. A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest, 1999, 104, 1191-1197.
151. Ge, J.; Zhao, G.; Chen, R.; Li, S.; Wang, S.; Zhang, X.; Zhuang, Y.; Du, J.; Yu, X.; Li, G.; Yang, Y. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail, 2006, 8, 284-289.
152. Sam, F.; Siwik, D. A. Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure. Hypertension, 2006, 48, 830-831.
153. Liu, J.; Sukhova, G. K.; Sun, J. S.; Xu, W. H.; Libby, P.; Shi, G. P. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol, 2004, 24, 1359-1366.
154. Lindholt, J. S.; Erlandsen, E. J.; Henneberg, E. W. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg, 2001, 88, 1472-1475.
155. Lv, B. J.; Lindholt, J. S.; Cheng, X.; Wang, J.; Shi, G. P. Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study. PLoS One, 2012, 7, e41813.
156. Abisi, S.; Burnand, K. G.; Waltham, M.; Humphries, J.; Taylor, P. R.; Smith, A. Cysteine protease activity in the wall of abdominal aortic aneurysms. J Vasc Surg, 2007, 46, 1260-1266.
157. Abdul-Hussien, H.; Soekhoe, R. G.; Weber, E.; von der Thusen, J. H.; Kleemann, R.; Mulder, A.; van Bockel, J. H.; Hanemaaijer, R.; Lindeman, J. H. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol, 2007, 170, 809-817.
158. Sukhova, G. K.; Wang, B.; Libby, P.; Pan, J. H.; Zhang, Y.; Grubb, A.; Fang, K.; Chapman, H. A.; Shi, G. P. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res, 2005, 96, 368-375.
159. Bengtsson, E.; To, F.; Hakansson, K.; Grubb, A.; Branen, L.; Nilsson, J.; Jovinge, S. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2005, 25, 2151-2156.
160. Schulte, S.; Sun, J.; Libby, P.; Macfarlane, L.; Sun, C.; Lopez-Ilasaca, M.; Shi, G. P.; Sukhova, G. K. Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. Am J Pathol, 2010, 177, 456-463.
161. Cheng, X. W.; Kuzuya, M.; Sasaki, T.; Arakawa, K.; Kanda, S.; Sumi, D.; Koike, T.; Maeda, K.; Tamaya-Mori, N.; Shi, G. P.; Saito, N.; Iguchi, A. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol, 2004, 164, 243-251.
162. Madero, M.; Wassel, C. L.; Peralta, C. A.; Najjar, S. S.; Sutton-Tyrrell, K.; Fried, L.; Canada, R.; Newman, A.; Shlipak, M. G.; Sarnak, M. J. Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol, 2009, 20, 1086-1093.
163. Odaira, M.; Tomiyama, H.; Matsumoto, C.; Yamada, J.; Yoshida, M.; Shiina, K.; Nagata, M.; Yamashina, A. Association of serum cystatin C with pulse wave velocity, but not pressure wave reflection, in subjects with normal renal function or mild chronic kidney disease. Am J Hypertens, 2010, 23, 967-973.
164. Arpegard, J.; Ostergren, J.; de Faire, U.; Hansson, L. O.; Svensson, P. Cystatin C--a marker of peripheral atherosclerotic disease? Atherosclerosis, 2008, 199, 397-401.
165. Shlipak, M. G.; Sarnak, M. J.; Katz, R.; Fried, L. F.; Seliger, S. L.; Newman, A. B.; Siscovick, D. S.; Stehman-Breen, C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005, 352, 2049-2060.
166. Ni, L.; Lu, J.; Hou, L. B.; Yan, J. T.; Fan, Q.; Hui, R.; Cianflone, K.; Wang, W.; Wang, D. W. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke, 2007, 38, 3287-3288.
167. Hoke, M.; Amighi, J.; Mlekusch, W.; Schlager, O.; Exner, M.; Sabeti, S.; Dick, P.; Koppensteiner, R.; Minar, E.; Rumpold, H.; Wagner, O.; Schillinger, M. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke, 2010, 41, 674-679.
168. Deo, R.; Fyr, C. L.; Fried, L. F.; Newman, A. B.; Harris, T. B.; Angleman, S.; Green, C.; Kritchevsky, S. B.; Chertow, G. M.; Cummings, S. R.; Shlipak, M. G. Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J, 2008, 155, 62-68.
169. Bui, A. L.; Katz, R.; Kestenbaum, B.; de Boer, I. H.; Fried, L. F.; Polak, J. F.; Wasserman, B. A.; Sarnak, M. J.; Siscovick, D.; Shlipak, M. G. Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis, 2009, 53, 389-398.
170. O'Hare, A. M.; Newman, A. B.; Katz, R.; Fried, L. F.; Stehman-Breen, C. O.; Seliger, S. L.; Siscovick, D. S.; Shlipak, M. G. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med, 2005, 165, 2666-2670.
171. Urbonaviciene, G.; Shi, G. P.; Urbonavicius, S.; Henneberg, E. W.; Lindholt, J. S. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis, 2011, 216, 440-445.
172. Chen, J.; Mohler, E. R., 3rd; Xie, D.; Shlipak, M. G.; Townsend, R. R.; Appel, L. J.; Raj, D. S.; Ojo, A. O.; Schreiber, M. J.; Strauss, L. F.; Zhang, X.; Wang, X.; He, J.; Hamm, L. L. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol, 2012, 110, 136-141.
173. Shlipak, M. G.; Katz, R.; Sarnak, M. J.; Fried, L. F.; Newman, A. B.; Stehman-Breen, C.; Seliger, S. L.; Kestenbaum, B.; Psaty, B.; Tracy, R. P.; Siscovick, D. S. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med, 2006, 145, 237-246.
174. Sarnak, M. J.; Katz, R.; Stehman-Breen, C. O.; Fried, L. F.; Jenny, N. S.; Psaty, B. M.; Newman, A. B.; Siscovick, D.; Shlipak, M. G. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med, 2005, 142, 497-505.
175. Shlipak, M. G.; Katz, R.; Fried, L. F.; Jenny, N. S.; Stehman-Breen, C. O.; Newman, A. B.; Siscovick, D.; Psaty, B. M.; Sarnak, M. J. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol, 2005, 45, 268-271.
176. Alehagen, U.; Dahlstrom, U.; Lindahl, T. L. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail, 2009, 11, 354-360.
177. Lassus, J.; Harjola, V. P.; Sund, R.; Siirila-Waris, K.; Melin, J.; Peuhkurinen, K.; Pulkki, K.; Nieminen, M. S. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J, 2007, 28, 1841-1847.
178. Campbell, C. Y.; Clarke, W.; Park, H.; Haq, N.; Barone, B. B.; Brotman, D. J. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol, 2009, 104, 389-392.
179. Manzano-Fernandez, S.; Boronat-Garcia, M.; Albaladejo-Oton, M. D.; Pastor, P.; Garrido, I. P.; Pastor-Perez, F. J.; Martinez-Hernandez, P.; Valdes, M.; Pascual-Figal, D. A. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol, 2009, 103, 1753-1759.
180. Naruse, H.; Ishii, J.; Kawai, T.; Hattori, K.; Ishikawa, M.; Okumura, M.; Kan, S.; Nakano, T.; Matsui, S.; Nomura, M.; Hishida, H.; Ozaki, Y. Cystatin C in acute heart failure without advanced renal impairment. Am J Med, 2009, 122, 566-573.
181. Carrasco-Sanchez, F. J.; Galisteo-Almeda, L.; Paez-Rubio, I.; Martinez-Marcos, F. J.; Camacho-Vazquez, C.; Ruiz-Frutos, C.; Pujol-De La Llave, E. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail, 2011, 17, 31-38.
182. Moran, A.; Katz, R.; Smith, N. L.; Fried, L. F.; Sarnak, M. J.; Seliger, S. L.; Psaty, B.; Siscovick, D. S.; Gottdiener, J. S.; Shlipak, M. G. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail, 2008, 14, 19-26.
183. Ix, J. H.; Shlipak, M. G.; Chertow, G. M.; Ali, S.; Schiller, N. B.; Whooley, M. A. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail, 2006, 12, 601-607.
184. Ix, J. H.; Shlipak, M. G.; Chertow, G. M.; Whooley, M. A. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation, 2007, 115, 173-179.
185. Patel, P. C.; Ayers, C. R.; Murphy, S. A.; Peshock, R.; Khera, A.; de Lemos, J. A.; Balko, J. A.; Gupta, S.; Mammen, P. P.; Drazner, M. H.; Markham, D. W. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail, 2009, 2, 98-104.
186. Agarwal, S.; Thohan, V.; Shlipak, M. G.; Lima, J.; Bluemke, D. A.; Siscovick, D.; Gomes, A.; Herrington, D. M. Association between Cystatin C and MRI Measures of Left Ventricular Structure and Function: Multi-Ethnic Study of Atherosclerosis. Int J Nephrol, 2011, 2011, 153-868.
187. Tang, W. H.; Van Lente, F.; Shrestha, K.; Troughton, R. W.; Francis, G. S.; Tong, W.; Martin, M. G.; Borowski, A. G.; Jasper, S.; Starling, R. C.; Klein, A. L. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail, 2008, 14, 394-399.
188. Bishu, K.; Deswal, A.; Chen, H. H.; LeWinter, M. M.; Lewis, G. D.; Semigran, M. J.; Borlaug, B. A.; McNulty, S.; Hernandez, A. F.; Braunwald, E.; Redfield, M. M. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J, 2012.
189. Ichimoto, E.; Jo, K.; Kobayashi, Y.; Inoue, T.; Nakamura, Y.; Kuroda, N.; Miyazaki, A.; Komuro, I. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J, 2009, 73, 1669-1673.
190. Dupont, M.; Wu, Y.; Hazen, S. L.; Tang, W. H. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail, 2012, 5, 602-609.
191. Lee, M.; Saver, J. L.; Huang, W. H.; Chow, J.; Chang, K. H.; Ovbiagele, B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes, 2010, 3, 675-683.
192. Koenig, W.; Twardella, D.; Brenner, H.; Rothenbacher, D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem, 2005, 51, 321-327.
193. Luc, G.; Bard, J. M.; Lesueur, C.; Arveiler, D.; Evans, A.; Amouyel, P.; Ferrieres, J.; Juhan-Vague, I.; Fruchart, J. C.; Ducimetiere, P. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis, 2006, 185, 375-380.
194. Djousse, L.; Kurth, T.; Gaziano, J. M. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J, 2008, 155, 82-86.
195. Xie, L.; Terrand, J.; Xu, B.; Tsaprailis, G.; Boyer, J.; Chen, Q. M. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res, 2010, 87, 628-635.
196. Muntner, P.; Mann, D.; Winston, J.; Bansilal, S.; Farkouh, M. E. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol, 2008, 102, 54-57.
197. Deo, R.; Shlipak, M. G.; Ix, J. H.; Ali, S.; Schiller, N. B.; Whooley, M. A. Association of cystatin C with ischemia in patients with coronary heart disease. Clin Cardiol, 2009, 32, E18-22.
198. Keller, T.; Messow, C. M.; Lubos, E.; Nicaud, V.; Wild, P. S.; Rupprecht, H. J.; Bickel, C.; Tzikas, S.; Peetz, D.; Lackner, K. J.; Tiret, L.; Munzel, T. F.; Blankenberg, S.; Schnabel, R. B. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J, 2009, 30, 314-320.
199. Taglieri, N.; Fernandez-Berges, D. J.; Koenig, W.; Consuegra-Sanchez, L.; Fernandez, J. M.; Robles, N. R.; Sanchez, P. L.; Beiras, A. C.; Orbe, P. M.; Kaski, J. C. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis, 2010, 209, 300-305.
200. Windhausen, F.; Hirsch, A.; Fischer, J.; van der Zee, P. M.; Sanders, G. T.; van Straalen, J. P.; Cornel, J. H.; Tijssen, J. G.; Verheugt, F. W.; de Winter, R. J. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem, 2009, 55, 1118-1125.
201. Jernberg, T.; Lindahl, B.; James, S.; Larsson, A.; Hansson, L. O.; Wallentin, L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation, 2004, 110, 2342-2348.
202. Silva, D.; Cortez-Dias, N.; Jorge, C.; Marques, J. S.; Carrilho-Ferreira, P.; Magalhaes, A.; Martins, S. R.; Goncalves, S.; da Silva, P. C.; Fiuza, M.; Diogo, A. N.; Pinto, F. J. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol, 2012, 109, 1431-1438.
203. Akerblom, A.; Wallentin, L.; Siegbahn, A.; Becker, R. C.; Budaj, A.; Buck, K.; Giannitsis, E.; Horrow, J.; Husted, S.; Katus, H. A.; Steg, P. G.; Storey, R. F.; Asenblad, N.; James, S. K. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem, 2012, 58, 190-199.
204. Sun, T. W.; Xu, Q. Y.; Yao, H. M.; Zhang, X. J.; Wu, Q.; Zhang, J. Y.; Li, L.; Zhang, Y. Z.; Kan, Q. C.; Guan, F. X.; Wang, L. X. The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart Lung, 2012, 41, 456-462.
205. Niccoli, G.; Conte, M.; Della Bona, R.; Altamura, L.; Siviglia, M.; Dato, I.; Ferrante, G.; Leone, A. M.; Porto, I.; Burzotta, F.; Brugaletta, S.; Biasucci, L. M.; Crea, F. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis, 2008, 198, 373-380.
206. Kiyosue, A.; Hirata, Y.; Ando, J.; Fujita, H.; Morita, T.; Takahashi, M.; Nagata, D.; Kohro, T.; Imai, Y.; Nagai, R. Plasma Cystatin C Concentration Reflects the Severity of Coronary Artery Disease in Patients Without Chronic Kidney Disease. Circulation Journal, 2010, 74, 2441-2447.
207. Imai, A.; Komatsu, S.; Ohara, T.; Kamata, T.; Yoshida, J.; Miyaji, K.; Shimizu, Y.; Takewa, M.; Hirayama, A.; Deshpande, G. A.; Takahashi, O.; Kodama, K. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis, 2011, 218, 350-355.
208. Shlipak, M. G.; Katz, R.; Cushman, M.; Sarnak, M. J.; Stehman-Breen, C.; Psaty, B. M.; Siscovick, D.; Tracy, R. P.; Newman, A.; Fried, L. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med, 2005, 118, 1416.
209. Leung-Tack, J.; Tavera, C.; Gensac, M. C.; Martinez, J.; Colle, A. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res, 1990, 188, 16-22.